Quantcast

Industry news that matters to you.  Learn more

NIH to Fund Research on Alcohol-related Biomarkers

The National Institute on Alcohol Abuse and Alcoholism aims to fund small businesses and support the technology transfer of new biomarkers that can be used to detect alcohol-related organ damage and fetal exposure to alcohol, according to a new NIAAA grant notice.

NIH to Fund Research into Environmental Stress Biomarkers

The National Institute of Environmental Health Sciences will lead a program to give a total of $2.6 million for five or six projects over two years that seek to validate candidate biomarkers and technologies that measure biological responses to chemical toxicants and other environmental stressors.

Thermo Fisher Scientific and Intrinsic Bioprobes Announce Alliance in Mass Spectrometric Immunoassay Workflow Development

Thermo Fisher Scientific, Inc., the world leader in serving science, and Intrinsic Bioprobes (IBI) Inc., today announced an alliance to co-develop and market a mass spectrometry solution that will enable researchers to perform quantitative, high-throughput, high-resolution protein biomarker assays. The solution couples the specificity of immunoenrichment with the sensitivity and quantitative capability of mass spectrometry to provide researchers with a more complete, higher-resolution view of the proteome. Initially, via an exclusive reseller agreement, the solution will be applied to the detection of human parathyroid hormone (PTH) and its variants, which may be useful as biomarkers for bone diseases and diseases of the endocrine system.

Michael J. Fox Foundation Announces $1.1 Million to Advance Leading Biomarker Candidates for Parkinson’s Disease

The Michael J. Fox Foundation for Parkinson’s Research today announced nearly $1.1 million for projects aimed at advancing the development of leading biomarker candidates for Parkinson’s disease. The discovery and validation of biomarkers is of critical importance to increasing the speed and efficiency of PD therapeutic development, allowing scientists and clinicians to more accurately identify appropriate subjects for clinical studies, measure disease progression and monitor treatment effects in clinical trials.

Vermillion Announces Issuance of Patent for Alzheimer’s Disease Diagnosis

Vermillion, Inc., a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of a patent entitled “Biomarkers for Alzheimer’s disease” to the Company. The patent claims are directed to biomarker combinations for the diagnosis and management of Alzheimer’s disease and to the measurement of the biomarkers by a variety of methods, including mass spectrometry and immunoassay.